Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)

University of Toronto

$100,000.00

Outcomes Associated with Direct Rapid Genetic Testing at Time of Breast Cancer Diagnosis

FY 2019-20

Summary
Approximately 11% of all breast cancers are due to a mutation in a cancer predisposition gene, most frequently BRCA1 or BRCA2. These breast cancers should receive different treatments to increase the chance that a woman will survive, including bilateral mastectomy. However, women must know if they have a genetic mutation in a cancer causing gene at the time of diagnosis when treatment decisions are being made (rapid genetic testing). A new model of genetic testing at time of cancer diagnosis is needed to ensure equitable access to genetic testing for Canadian patients. Direct genetic testing offers patients limited to no pre-test discussion with a genetic counsellor, and written documents or other resources are provided. Our overall objective is to evaluate the impact of Direct Rapid Genetic Testing (DRGT) for breast cancer susceptibility genes in newly-diagnosed breast cancer patients on treatment and psychosocial outcomes, compared to women who received rapid genetic testing (RGT) with standard pre and post-test genetic counselling. We will recruit from 1000 women from hospitals throughout Canada, including those which do not have genetic counselling programs. Sequencing will be done on BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53, ATM, and CHEK2 genes. We will have one central genetic counsellor (Women's College Hospital) who will provide post-test counselling. Genetic test results will available in 7 days. Outcomes will be compared between those who received RGT with standard genetic counselling to those who received Direct Rapid Genetic Testing. The traditional cancer genetics model is not sustainable with the current volumes of genetic testing. This proposed delivery of RGT at the time of breast cancer diagnosis is responsive to the need for new models. This research has the potential to lead to the development of a sustainable and accessible model of genetic testing at the time of cancer diagnosis, which has a very high potential to improve patient outcomes.
Program
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
414020
Name
Metcalfe Kelly A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Health systems / services
Prcname2
Health Services Evaluation & Interventions Research 2
Projecttitle
Outcomes Associated with Direct Rapid Genetic Testing at Time of Breast Cancer Diagnosis
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Keyworddelim
Brca1; Brca2; Breast Cancer; Genetic Testing; Treatment
Abstract
Approximately 11% of all breast cancers are due to a mutation in a cancer predisposition gene, most frequently BRCA1 or BRCA2. These breast cancers should receive different treatments to increase the chance that a woman will survive, including bilateral mastectomy. However, women must know if they have a genetic mutation in a cancer causing gene at the time of diagnosis when treatment decisions are being made (rapid genetic testing). A new model of genetic testing at time of cancer diagnosis is needed to ensure equitable access to genetic testing for Canadian patients. Direct genetic testing offers patients limited to no pre-test discussion with a genetic counsellor, and written documents or other resources are provided. Our overall objective is to evaluate the impact of Direct Rapid Genetic Testing (DRGT) for breast cancer susceptibility genes in newly-diagnosed breast cancer patients on treatment and psychosocial outcomes, compared to women who received rapid genetic testing (RGT) with standard pre and post-test genetic counselling. We will recruit from 1000 women from hospitals throughout Canada, including those which do not have genetic counselling programs. Sequencing will be done on BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53, ATM, and CHEK2 genes. We will have one central genetic counsellor (Women's College Hospital) who will provide post-test counselling. Genetic test results will available in 7 days. Outcomes will be compared between those who received RGT with standard genetic counselling to those who received Direct Rapid Genetic Testing. The traditional cancer genetics model is not sustainable with the current volumes of genetic testing. This proposed delivery of RGT at the time of breast cancer diagnosis is responsive to the need for new models. This research has the potential to lead to the development of a sustainable and accessible model of genetic testing at the time of cancer diagnosis, which has a very high potential to improve patient outcomes.
Competitiondate
201909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Metcalfe, Kelly A; Eisen, Andrea F
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~